Modality
Degrader
MOA
STINGag
Target
MET
Pathway
T-cell
CSU
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
Feb 2020
→ Mar 2025
Phase 2Current
NCT05950658
585 pts·CSU
2020-02→2025-03·Completed
585 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-03-171.0y agoPh3 Readout· CSU
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P2/3
Complet…
Catalysts
Ph3 Readout
2025-03-17 · 1.0y ago
CSU
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05950658 | Phase 2/3 | CSU | Completed | 585 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| Tezelucimab | Ascendis Pharma | Preclinical | SHP2 |